Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis

IMPORTANCE: Uncertainty remains about how aggressively to treat early multiple sclerosis. High-efficacy disease-modifying therapies (DMTs) are often reserved for individuals expressing poor prognostic features at baseline. OBJECTIVE: To analyze long-term outcomes in a population-based cohort accordi...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:JAMA Neurol
Autori principali: Harding, Katharine, Williams, Owain, Willis, Mark, Hrastelj, James, Rimmer, Anthony, Joseph, Fady, Tomassini, Valentina, Wardle, Mark, Pickersgill, Trevor, Robertson, Neil, Tallantyre, Emma
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Medical Association 2019
Soggetti:
Original Investigation
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6515582/
https://ncbi.nlm.nih.gov/pubmed/30776055
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaneurol.2018.4905
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi